Ovarian cancer: surgery first or chemotherapy before surgery?

For advanced epithelial ovarian cancer, one centre may recommend surgery first while another proposes drug treatment followed by reassessment for an operation. The choice relates to the prospect of removing visible disease adequately and the patient’s ability to undergo the procedure safely. Neither “always operate first” nor “always shrink the tumour first” is a reliable rule for every case.

Confirm which disease the proposal addresses

Ovarian tumours are not one diagnosis. Epithelial cancer, a borderline tumour, a germ-cell tumour and metastasis from another organ raise different questions. Provide the complete pathology where available and identify how the sample was obtained. If the diagnosis remains suspected from investigations, preserve that distinction in the referral.

This discussion concerns sequencing in epithelial ovarian cancer and related conditions assessed by a gynaecologic oncology team. It does not imply that chemotherapy before surgery is appropriate for every adnexal mass. CA-125 results and imaging are considered alongside other information rather than replacing a complete diagnosis.

Understand the objective of cytoreduction

Cytoreductive surgery aims to remove tumour deposits. In advanced disease, the anticipated operation may extend beyond the ovaries, so possible additional procedures need discussion before consent. Assessment concerns expected benefit and risk for the individual patient as well as technical feasibility.

NCI discusses surgery and systemic treatment in different sequences, including chemotherapy before interval surgery in selected circumstances. Its professional summary emphasizes the importance of the cytoreductive result and patient selection. NCI: professional summary of ovarian cancer treatment.

Removing all visible tumour is different from removing every cancer cell from the body. Even after complete visible cytoreduction, the question of systemic treatment remains separate. Being offered chemotherapy after an extensive operation does not itself mean the surgery was performed badly.

The diameter of the ovarian mass alone also does not describe surgical complexity. Small deposits in several abdominal locations may create different problems from one large mass distributed differently. Ask the surgeon which sites determine the feasibility of the proposed procedure. This helps explain why two people with the same broad stage can receive different recommendations about which phase should come first.

Provide information that informs the first step

Collect original CT or MRI files, reports describing disease distribution, pathology and records of previous interventions. If diagnostic laparoscopy has been performed, the complete operative record can help the receiving team understand what was assessed. Where treatment has already started, include drug names, cycle dates, tolerability and response investigations.

Describe food intake, weight loss, other illnesses, substantial abdominal swelling and current independence. These details matter when evaluating readiness for complex surgery and systemic treatment. Omitting a problem to obtain an earlier invitation would make the preliminary plan less reliable. The proposal needs to reflect the patient’s actual health.

If chemotherapy before surgery is proposed

Ask what the initial stage aims to achieve and when another surgical discussion will occur. Establish which findings will be used to assess response and possible resectability. The regimen and number of cycles are individual clinical decisions. Receiving the treatment does not guarantee that an operation will follow or that its extent can be predicted in advance.

Identify who will make the decision after reassessment. If systemic treatment takes place at home and surgery is being considered in Turkey, the teams need an agreed route for sharing images and reports. A fall in one tumour marker alone is not an adequate substitute for the full clinical evaluation.

If surgery first is proposed

Ask what supports the possibility of adequate cytoreduction, which specialists may be needed and how potential procedures involving neighbouring organs will be discussed. Clarify recovery, nutritional support, possible additional expenses and subsequent oncology treatment. Written consent should reflect the actual scope under consideration.

When opinions differ, provide the same records to both teams and ask for the specific reason. The guides to an oncology second opinion and comparing complete proposals help organize this discussion. The goal is an understandable sequence with explicit conditions for reassessment, rather than competing promises to perform a more extensive operation. Before travel, also confirm the immediate step and who remains responsible while the review is underway.